|
|
Article: Seeing and Treating Cholinergic Deficits in AD.(Alzheimer's disease)
- Article from:
- Neurology Alert
- Article date:
- May 1, 1999
- Author:
CopyrightCOPYRIGHT 1999 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ABSTRACTS & COMMENTARY
Sources: Imbimbo BP, et al. Efficacy and safety of epistigmine for the treatment of patients with AD. Neurology 1999;52(4):700-708; Kuhl DE, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and AD. Neurology 1999;52(4):691-699.
ALZHEIMER'S DISEASE (AD) PROGRESSES SLOWLY, necessitating many years to fully assess the efficacy of new treatments. One small step consists of the outcome of a randomized trial of epistigmine, yet another acetylcholinesterase inhibitor (AChEI) being tested for ameliorating AD-related dementia. Epistagmine given 15 mg tid previously showed marginal improvement in AD patients, but ...